Santos et al. report that stiffness sensing through microtubules drives fibroblast activation in mouse models of fibrotic disease. In the cover image, fluorescence microscopy of activated fibroblasts highlights the polarized microtubule network (green), revealing an unexpected role for microtubules as active drivers of cellular mechanosensing in fibrotic disease. By converting tissue stiffness into profibrotic signals, this microtubule network sustains fibroblast activation and reinforces fibrosis progression. These findings identify microtubule mechanotransduction as a potential therapeutic target across fibrotic diseases. Microtubules are shown in green, F-actin stress fibers in red, and nuclei in blue.
Background: Whether circadian rhythm disruption (CRD) promotes fibrotic remodeling after septic lung injury remains unclear. We tested whether CRD drives this process through macrophage CLOCK–PIEZO1 signaling. Methods: Lung specimens from patients with sepsis-associated lung injury and non-injured controls were analyzed alongside public murine lung transcriptomic datasets. Mice underwent cecal ligation and puncture or sham surgery and were maintained under stable or repeatedly shifted light–dark cycles; selected experiments included LysM-lineage Piezo1 deletion. Day-3 lung injury and day-28 fibrosis were assessed, and mechanisms were defined using genetic, biochemical and co-culture approaches. Results: CRD suppressed CLOCK expression in macrophage-lineage cells, leading to increased PIEZO1 expression and aggravated collagen deposition. CLOCK repressed Piezo1 transcription through a promoter E-box. Loss of myeloid Clock reduced Clock mesor and amplitude by 66.3% and 90.3%, respectively, increased Piezo1 mesor by 54.0%, and produced genotype-by-rhythm interactions for both genes (P < 0.0001). PIEZO1 activation impaired lysosomal acid lipase (LAL)–dependent lipophagy and promoted ZDHHC19-mediated peptidylarginine deiminase 4 (PAD4) palmitoylation and extracellular-trap formation. LysM-lineage Piezo1 deletion attenuated fibrosis. PIEZO1 inhibition or DNase I reduced epithelial injury and fibroblast activation induced by extracellular DNA-rich macrophage signals. Conclusions: CRD promotes post-septic fibrosis through a CLOCK–PIEZO1-linked macrophage immunometabolic program, identifying PIEZO1, extracellular DNA-rich traps and impaired lipid clearance as candidate targets.
Xiaohua Wang, Aming Sang, Wei Wang, Yujia Liu, Zirui Zhao, Haoxiang Li, Xiaoqi Xiong, Jie Cai, Ming Xu, Xinyi Li
Duchenne muscular dystrophy (DMD) is a fatal genetic disorder characterized by skeletal muscle degeneration and cardiomyopathy. Effective cardiac therapies remain limited. This study investigated the therapeutic potential of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (EMPA) in the dystrophin-deficient DBA2/J-mdx mouse model of DMD. Male mice received control chow or EMPA-containing chow (~25mg/kg/day), and cardiac function was evaluated longitudinally using four-dimensional ultrasound imaging. EMPA did not alter left ventricular mass or volume but delayed the onset of systolic dysfunction, preserving ejection fraction (EF) for 12 weeks and maintaining significantly higher EF through 24 weeks. EMPA also attenuated progressive impairments in systolic and diastolic myocardial deformation. Functional preservation was accompanied by reduced cardiomyocyte hypertrophy and reduced expression of cardiac stress genes. EMPA increased mtDNA copy number, reduced mtDNA damage, preserved the mtDNA-encoded respiratory chain protein MT-CO1, and increased myocardial ATP content, supporting improved mitochondrial integrity and myocardial energetic capacity. In addition, EMPA induced transcriptional changes consistent with enhanced fatty acid and ketone metabolism. Systemically, EMPA improved growth trajectory, preserved relative lean mass, increased skeletal muscle torque, attenuated fiber-type remodeling, and did not adversely affect renal function. Together, these findings support SGLT2 inhibitors as a promising therapeutic strategy for DMD-associated cardiomyopathy.
Benjamin J. Zeidler, Connor Thomas, John P. Salvas, Areli Jannes S. Javier, Alyssa M. Richards, Linda A. Bean, Conner C. Earl, Akanksha Agrawal, Niharika Narra, Steven N. Kozakiewicz, Lifan Zeng, Carol A Witczak, Joshua R Huot, Il-Man Kim, Meena S. Madhur, Mark C. Kowala, Larry W. Markham, Craig J. Goergen, Steven S. Welc
Monocyte-derived DC therapies programmed for robust IL-12p70 production have been associated with favorable outcomes in cancer clinical trials. However, clinical responses remain inconsistent even under standardized protocols, and the cellular basis for this variability is unknown. We leveraged single-cell multiomics to characterize two widely used DC platforms, the high-IL-12p70-producing α-Type-1-polarized DC (αDC1) and the IL-12p70-deficient DC induced in the presence of PGE 2 (PGE2-DC), at baseline and following rhCD40L activation. DC generated from 7 healthy participants representing the spectrum of rhCD40L-induced IL-12p70 production were profiled by transcriptome analysis with 42-plex surface proteomics, multiplex ELISA, and ELISpot quantification of IL-12p70-producing cells. While αDC1 and PGE2-DC distinctly responded to rhCD40L, αDC1 alone comprised 3 transcriptionally and phenotypically distinct subpopulations in resting and stimulated states. Only a limited fraction of αDC1 coexpressed IL12A and IL12B (IL-12p70 producers), confirmed by ELISpot at the protein level. The distribution of αDC1 subclusters varied markedly between individuals and correlated with bulk cytokine and chemokine secretion profiles. Magnetic enrichment on the surface marker CD116 yielded αDC1 fractions that differentially primed naïve CD4 + T cells, demonstrating these subpopulations are functionally divergent and separable. This heterogeneity may underlie inconsistent clinical outcomes, providing a rationale for subcluster-based release criteria and patient stratification.
Allison E. DePuyt, Peter E. J. Shoucair, Holly A. Bilben, Jeremy Martinson, Bernard J.C. Macatangay, Charles Rinaldo, Pawel Kalinski, Robbie B. Mailliard
Yuning Liu, Yang Li, Aditya Surapaneni, Matthew Muller, Carina M. Flaherty, Bing Yu, Eugene P. Rhee, Zulema Rodriguez-Hernandez, Pascal Schlosser, Jonathan D Newman, Kelly V. Ruggles, Jeffrey S. Berger, Morgan E. Grams
The etiology of severe left-sided obstructive lesions (LSOL) of the heart, a common form of congenital heart disease (CHD), often remains unknown even after comprehensive genetic testing. Preclinical models implicate placental perturbations in abnormal cardiogenesis; however, little is known about connections between human placenta and fetal cardiac diseases. We profiled term placentas from severe LSOL pregnancies (n = 20) with and without placental pathologies and healthy controls (n = 10) to test whether severe fetal LSOL is associated with distinct transcriptomic and cellular states. Bulk RNA-sequencing of archival formalin-fixed paraffin-embedded tissues identified 1,030 differentially expressed protein-coding genes (580 [up], 450 [down]). Upregulated programs involved heart-valve development, endothelial signaling, and extracellular-matrix processes; while endocrine, trophoblast and gamma-aminobutyric acid signaling processes were downregulated. Severe LSOL pregnancies with histologically normal placentas showed enrichment of lymphatic-vascular development and cyclic-nucleotide signaling. Digital deconvolution analysis inferred reduced trophoblast fractions with reciprocal increase in endothelial and immune cell types. These findings support a unique placental gene expression in abnormal cardiac development, even in the absence of overt placental histopathology. These RNA expression signatures may serve as candidate biomarkers and lay the groundwork for mechanistic studies of the heart-placenta axis and future risk stratification in pregnancies with fetuses diagnosed with severe LSOL.
Rachel L. Leon, Huan Lu, Maria M. Ossa Galvis, Imran N. Mir, Bowen Xiong, Tao Wang, Durga Udayakumar